At the 2026 American Association for Cancer Research (AACR) meeting, Chinese researchers unveiled a wave of home‑grown cancer breakthroughs, headlined by the first‑in‑human study of SynKIR‑110. The novel therapy, designed to unleash the immune system against tumors, demonstrated an excellent safety profile with no dose‑limiting toxicities and early signs of tumor shrinkage across multiple solid‑tumor types. The conference also highlighted several other promising Chinese candidates. Oral cell‑cycle inhibitor CID‑078 showed good absorption and tolerability in patients with relapsed or refractory solid cancers. Next‑generation KRAS blockers Elisrasib and Zoldonrasib delivered durable responses in KRAS‑mutant lung cancer, even after prior treatments. The antibody‑drug conjugate SYS6010 produced encouraging activity in advanced nasopharyngeal carcinoma, while the combination of the small‑molecule Ris‑Rez with the immune checkpoint inhibitor Adebrelimab hinted at added benefit for non‑squamous NSCLC lacking driver mutations. Innovative approaches extended beyond drugs: a single‑cell sequencing study mapped the immune bottleneck in early‑stage lung adenocarcinoma, revealing a narrow window for immune‑based interventions. Finally, pairing HER2‑targeted DS‑8201 with intermittent olaparib proved tolerable, and QLS5132 showed dual efficacy and safety in platinum‑resistant ovarian cancer. Together, these results underscore China’s rising role in cutting‑edge oncology research.
Read more